Takatsuka Ibuki, Hirata Hiroya, Takahashi Takumi, Dohtan Satoshi, Oka Shinichiro, Sakamoto Nami, Takaba Masamitsu, Adachi Miwa, Takemura Tomonari, Nagata Yasuyuki, Ono Takaaki
Division of Hematology, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.
Leuk Res Rep. 2022 Apr 19;17:100312. doi: 10.1016/j.lrr.2022.100312. eCollection 2022.
A 52-year-old man was diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP). He experienced bosutinib-induced pulmonary arterial hypertension (PAH) recurrence following dasatinib use. Symptoms and examination findings associated with PAH improved after bosutinib cessation. Although nilotinib was started because of the loss of response after bosutinib cessation, a deep molecular response without PAH recurrence was achieved 3 months after the initiation of nilotinib therapy. PAH recurrence after switching to bosutinib due to dasatinib-induced PAH should be closely monitored. In addition, nilotinib therapy might be an effective approach in PAH cases related to dasatinib and/or bosutinib in patients with CML-CP.
一名52岁男性被诊断为慢性期慢性髓性白血病（CML-CP）。他在使用达沙替尼后出现了博舒替尼诱导的肺动脉高压（PAH）复发。停用博舒替尼后，与PAH相关的症状和检查结果有所改善。尽管由于停用博舒替尼后失去反应而开始使用尼洛替尼，但在尼洛替尼治疗开始3个月后实现了深度分子反应且无PAH复发。对于因达沙替尼诱导的PAH而改用博舒替尼后PAH复发的情况应密切监测。此外，尼洛替尼治疗可能是CML-CP患者中与达沙替尼和/或博舒替尼相关的PAH病例的一种有效方法。
